Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05170113 · ClinicalTrials.gov registry record · NA

Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health

A NA study of Fatigue, sponsored by Supplement Formulators.

Completed
Registry status
NA
Development phase
79
Enrollment target
1
Study location

NCT05170113 is a NA study of Fatigue that has completed, run by Supplement Formulators. The registered enrollment target is 79 participants, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05170113, a NA study of Fatigue, has completed, sponsored by Supplement Formulators.

COMPLETED
Registry status
NA
Development phase
79 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the effectiveness and safety of the Alpinia galanga formulation, Theacrine formulation, and Caffeine formulation on fatigue, mental acuity, and cognitive health among overall healthy participants

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Alpinia galanga formulation
  • DIETARY_SUPPLEMENT Theacrine formulation
  • DIETARY_SUPPLEMENT Caffeine formulation

Study Locations (1)

Florida

  • Life Extension Clinical Research - Fort Lauderdale

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2021-11-02
Est. Completion 2022-05-31
Phase NA

Sponsor

Supplement Formulators

14 total trials

What the Registry Record Tells You About NCT05170113

The ClinicalTrials.gov registry entry for NCT05170113 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (64% lower). The listed sponsor is Supplement Formulators, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fatigue appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT05170113 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05170113 about?

NCT05170113 is a clinical study titled "Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health". The purpose of this study is to assess the effectiveness and safety of the Alpinia galanga formulation, Theacrine formulation, and Caffeine formulation on fatigue, mental acuity, and cognitive health among overall healthy participants

What is the current status of trial NCT05170113?

This trial is currently completed. It is a NA study. The enrollment target is 79 participants. The study started on 2021-11-02. Estimated completion is 2022-05-31.

What conditions does trial NCT05170113 study?

This clinical trial studies the following conditions: Fatigue.

What interventions are being tested in trial NCT05170113?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Alpinia galanga formulation (DIETARY_SUPPLEMENT), Theacrine formulation (DIETARY_SUPPLEMENT), Caffeine formulation (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05170113?

This trial is sponsored by Supplement Formulators, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05170113 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fatigue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.